529685
Prodigiosin Serratia marcescens
A cell-permeable tripyrrole alkaloid compound that displays immunosuppressive and anti-tumor properties irrespective of p53 status and multidrug resistance.
别名:
Prodigiosin Serratia marcescens, Casein Kinase I Inhibitor IV, 2-Methyl-3-pentyl-6-methoxyprodigiosene, NSC 47147
登录并加购，请在购物车里查看协议价、货期和发货地。
选择规格
变更视图
关于此项目
Assay:
≥95% (HPLC)
Form:
solid
Storage condition:
OK to freeze, protect from light
Quality Segment
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
dark red
solubility
DMF: soluble, DMSO: soluble, ethanol: soluble, methanol: soluble
shipped in
ambient
storage temp.
−20°C
SMILES string
CC1=C(CCCCC)C=C(/C=C2N=C(C3=CC=CN3)C=C\2OC)N1
InChI
1S/C20H25N3O/c1-4-5-6-8-15-11-16(22-14(15)2)12-19-20(24-3)13-18(23-19)17-9-7-10-21-17/h7,9-13,22-23H,4-6,8H2,1-3H3/b18-17+,19-12+
InChI key
WKGQSEFBQTWRPT-FHUUTLRSSA-N
General description
A cell-permeable tripyrrole alkaloid compound that displays immunosuppressive and anti-tumor properties irrespective of p53 status and multidrug resistance. Shown to selectively upregulate p21WAF/CIP1 and NAG-1 (nonsteroidal anti-inflammatory drug-activated gene 1) and downregulate survivin expression levels, induce mitochondria-mediated apoptosis and cell cycle arrest in tumor cells. Prevents FADD phosphorylation (IC50 = 2.0 µM in A549-FKR cells) through inhibition of FADD-kinase CK1α (IC50 ~ 6.0 µM in SW620-BGCR cells) and augments cisplatin (Cat. No. 232120)-induced apoptosis. Blocks NF-κB activation by decreasing pIκBα (by 63% at 3 µM) and IκBα levels in A549 cells, and shrinks tumor growth in A549-FKR tumor xenograft mouse model (3 mg/kg, i.p., o.d.).
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
Schinske, K.A., et al. 2011. Mol. Cancer Ther.10, 1807.
Chang, C.C., et al. 2011. J. Biosci. Bioeng.5, 501
Ho, T.F., et al. 2009. Toxicol. Appl. Pharmacol.235, 253
Soto-Cerrato, V., et al. 2007.Mol. Cancer Ther.6, 362.
Chang, C.C., et al. 2011. J. Biosci. Bioeng.5, 501
Ho, T.F., et al. 2009. Toxicol. Appl. Pharmacol.235, 253
Soto-Cerrato, V., et al. 2007.Mol. Cancer Ther.6, 362.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable